TMCnet News
AMARANTUS BIOSCIENCE HOLDINGS, INC. FILES (8-K) Disclosing Change in Directors or Principal Officers(Edgar Glimpses Via Acquire Media NewsEdge) Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective August 29, 2014, Iain Ross was appointed as a director and Chairman of the Audit Committee of the Board of Directors of Amarantus Bioscience Holdings, Inc. (the "Company"). Following a career with multi-national companies including Sandoz, Fisons plc and Hoffman La Roche, Mr Ross joined the Board of Celltech Group plc in 1991 and was responsible for building Celltech Biologics, the contract manufacturing division which was later sold to Alusuisse Lonza. For the last 18 years he has undertaken a number of start-ups and development stage companies as a board member on behalf of private equity groups and banks, including Quadrant Healthcare plc, Allergy Therapeutics Ltd, Eden Biodesign Ltd, Phadia AB and Silence Therapeutics plc. Currently Mr. Ross is Chairman of the Board of Ark Therapeutics Group PLC and Biomer Technology Ltd, and is also a Non-Executive Director of Benitec Biopharma Limited , Novogen Limited and Tissue Therapies Ltd each of which is traded on the Australian Securities Exchange. He is a Qualified Chartered Director of the UK Institute of Directors and Vice Chairman of the Council of Royal Holloway, University of London. Mr. Ross has no family relationship with any of the executive officers or directors of the Company. There are no arrangements or understandings between Mr. Ross and any other person pursuant to which he was appointed as a director of the Company. A copy of the Company's press release announcing Mr. Ross's appointment is attached as Exhibit 99.1 to this Current Report on Form 8-K. |